BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18385203)

  • 21. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.
    Viens P; Petit T; Yovine A; Bougnoux P; Deplanque G; Cottu PH; Delva R; Lotz JP; Belle SV; Extra JM; Cvitkovic E
    Ann Oncol; 2006 Mar; 17(3):429-36. PubMed ID: 16500913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
    Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
    Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    Einhorn LH; Brames MJ; Juliar B; Williams SD
    J Clin Oncol; 2007 Feb; 25(5):513-6. PubMed ID: 17290059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
    Kollmannsberger C; Nichols C; Bokemeyer C
    Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer.
    Delaloge S; Laadem A; Taamma A; Chouaki N; Cvitkovic E; Pautier P; Misset JL; Lhommé C
    Am J Clin Oncol; 2000 Dec; 23(6):569-74. PubMed ID: 11202798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
    Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
    Kuo DY; Blank SV; Christos PJ; Kim M; Caputo TA; Pothuri B; Hershman D; Goldman N; Ivy PS; Runowicz CD; Muggia F; Goldberg GL; Einstein MH
    Gynecol Oncol; 2010 Mar; 116(3):442-6. PubMed ID: 19931137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience.
    Faivre S; Kalla S; Cvitkovic E; Bourdon O; Hauteville D; Dourte LM; Bensmaïne MA; Itzhaki M; Marty M; Extra JM
    Ann Oncol; 1999 Sep; 10(9):1125-8. PubMed ID: 10572615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.
    Kawai K; Miyazaki J; Tsukamoto S; Hinotsu S; Hattori K; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2003 Mar; 33(3):127-31. PubMed ID: 12672789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
    Perez-Somarriba M; Moreno-Tejero ML; Rozas MI; Pelaez I; Madero L; Lassaletta A
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28089. PubMed ID: 31724795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
    Nishikawa M; Miyake H; Fujisawa M
    Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platinum-refractory germ cell tumors: an update on current treatment options and developments.
    Oing C; Alsdorf WH; von Amsberg G; Oechsle K; Bokemeyer C
    World J Urol; 2017 Aug; 35(8):1167-1175. PubMed ID: 27449639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
    Uchida M; Kawai K; Kimura T; Ichioka D; Takaoka E; Suetomi T; Miyazaki J; Nishiyama H
    Int J Clin Oncol; 2014 Dec; 19(6):1112-7. PubMed ID: 24647526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
    Nonomura N; Oka D; Nishimura K; Nakayama M; Inoue H; Mizutani Y; Miki T; Okuyama A
    Int J Urol; 2007 Jun; 14(6):527-31. PubMed ID: 17593098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
    Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
    J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
    Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Recková M; Mego M; Hlavatá Z; Brozmanová K; Risnyovzská Z; Svetlovská D; Koza I
    Neoplasma; 2007; 54(3):240-5. PubMed ID: 17447857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
    Nicolai N; Necchi A; Gianni L; Piva L; Biasoni D; Torelli T; Stagni S; Milani A; Pizzocaro G; Salvioni R
    BJU Int; 2009 Aug; 104(3):340-6. PubMed ID: 19239440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
    Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.
    Dieras V; Bougnoux P; Petit T; Chollet P; Beuzeboc P; Borel C; Husseini F; Goupil A; Kerbrat P; Misset JL; Bensmaïne MA; Tabah-Fisch I; Pouillart P
    Ann Oncol; 2002 Feb; 13(2):258-66. PubMed ID: 11886003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.